Esparza José
Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA.
Vaccine. 2013 Aug 2;31(35):3502-18. doi: 10.1016/j.vaccine.2013.05.018. Epub 2013 May 21.
Soon after HIV was discovered as the cause of AIDS in 1983-1984, there was an expectation that a preventive vaccine would be rapidly developed. In trying to achieve that goal, three successive scientific paradigms have been explored: induction of neutralizing antibodies, induction of cell mediated immunity, and exploration of combination approaches and novel concepts. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. In 2009, the field was reinvigorated with the modest results obtained from the RV144 trial conducted in Thailand. Here, we review those vaccine development efforts, with an emphasis on events that occurred during the earlier years. The goal is to provide younger generations of scientists with information and inspiration to continue the search for an HIV vaccine.
1983年至1984年期间,人类免疫缺陷病毒(HIV)被发现是获得性免疫缺陷综合征(AIDS,艾滋病)的病因后不久,人们就期望能迅速研制出预防性疫苗。为实现这一目标,人们探索了三种相继的科学范式:诱导中和抗体、诱导细胞介导免疫以及探索联合方法和新概念。尽管在理解HIV疫苗研发的科学基础方面已取得重大进展,但疗效试验对推动该领域发展至关重要。2009年,在泰国进行的RV144试验取得的适度结果为该领域注入了新的活力。在此,我们回顾那些疫苗研发工作,重点关注早期发生的事件。目标是为年轻一代科学家提供信息和灵感,以继续寻找HIV疫苗。